UCB (STU:UNC) Piotroski F-Score: 9 (As of Jun. 27, 2026) — 29% Above Median


STU:UNC UCB SA STU:UNC
89 GF Score
Price €257.90
GF Value €210.28
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is UCB Piotroski F-Score?

UCB STU:UNC +0.66% 89 Piotroski F-Score is 9 as of Jun. 27, 2026, which is 29% above its 10-year median of 7.00. GuruFocus rates STU:UNC with a GF Score™ of 89/100 and a GF Value™ of €210.28 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 1,342 Biotechnology companies, UCB ranks better than 99.93% on this metric.

Good Sign:

Piotroski F-Score is 9, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

UCB has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for UCB's Piotroski F-Score or its related term are showing as below:

STU:UNC' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 7   Max: 9
Current: 9

During the past 13 years, the highest Piotroski F-Score of UCB was 9. The lowest was 3. And the median was 7.

UCB  (STU:UNC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


UCB Piotroski F-Score Related Terms


UCB Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for UCB's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Piotroski F-Score Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 3.00 4.00 9.00 9.00

UCB Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 0.00 9.00 0.00 9.00

STU:UNC vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, UCB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UCB Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where UCB's Piotroski F-Score falls into.


STU:UNC
89GF Score
UCB SA STU:UNC
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was €1,558 Mil.
Cash Flow from Operations was €2,291 Mil.
Revenue was €7,741 Mil.
Gross Profit was €5,751 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (17347 + 18158) / 2 = €17752.5 Mil.
Total Assets at the begining of this year (Dec24) was €17,347 Mil.
Long-Term Debt & Capital Lease Obligation was €2,183 Mil.
Total Current Assets was €6,054 Mil.
Total Current Liabilities was €4,401 Mil.
Net Income was €1,065 Mil.

Revenue was €6,152 Mil.
Gross Profit was €4,400 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (15539 + 17347) / 2 = €16443 Mil.
Total Assets at the begining of last year (Dec23) was €15,539 Mil.
Long-Term Debt & Capital Lease Obligation was €2,963 Mil.
Total Current Assets was €4,788 Mil.
Total Current Liabilities was €3,529 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

UCB's current Net Income (TTM) was 1,558. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

UCB's current Cash Flow from Operations (TTM) was 2,291. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=1558/17347
=0.0898138

ROA (Last Year)=Net Income/Total Assets (Dec23)
=1065/15539
=0.06853723

UCB's return on assets of this year was 0.0898138. UCB's return on assets of last year was 0.06853723. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

UCB's current Net Income (TTM) was 1,558. UCB's current Cash Flow from Operations (TTM) was 2,291. ==> 2,291 > 1,558 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=2183/17752.5
=0.1229686

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=2963/16443
=0.18019826

UCB's gearing of this year was 0.1229686. UCB's gearing of last year was 0.18019826. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=6054/4401
=1.37559646

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=4788/3529
=1.35675829

UCB's current ratio of this year was 1.37559646. UCB's current ratio of last year was 1.35675829. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

UCB's number of shares in issue this year was 194.183. UCB's number of shares in issue last year was 194.547. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=5751/7741
=0.74292727

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4400/6152
=0.71521456

UCB's gross margin of this year was 0.74292727. UCB's gross margin of last year was 0.71521456. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=7741/17347
=0.44624431

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=6152/15539
=0.39590707

UCB's asset turnover of this year was 0.44624431. UCB's asset turnover of last year was 0.39590707. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+1+1+1
=9

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

UCB has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 9 mean?
UCB (STU:UNC) has a Piotroski F-Score of 9 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on UCB and its competitors. This is 29% above median its historical median of 7.00. Over the past decade, UCB's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, UCB ranks #1 out of 1342 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is UCB's Piotroski F-Score too high?
UCB's current Piotroski F-Score of 9 is 29% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Biotechnology industry median Piotroski F-Score is 3.00. UCB's value of 9 is 200% above this industry median. Based on the distribution chart, UCB ranks #1 out of 1342 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UCB has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #1 out of 1342 companies for Piotroski F-Score. This places UCB in the top 0% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. UCB's value of 9 is 200% above this benchmark. Historically, UCB's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 3.00, UCB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UCB's current Piotroski F-Score of 9 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on UCB and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UCB's current Piotroski F-Score is 9, which is 29% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Overvalued. The stock's GF Value™ is €210.28, compared to a current price of €257.90 — trading 22.6% above its estimated fair value. The current Piotroski F-Score is 9, which is 29% above median its 10-year median of 7.00 and 200% above the Biotechnology industry median of 3.00. UCB's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For UCB (STU:UNC), the current Piotroski F-Score is 9 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €257.90 is trading 22.6% above its estimated GF Value™ of €210.28. GuruFocus considers UCB to be Modestly Overvalued.

Key valuation signals for STU:UNC:

  • Piotroski F-Score: 9 (29% above median its 10-year median of 7.00)
  • GF Value™: €210.28 vs. price of €257.90 (22.6% above fair value)
  • GF Score™: 89/100 with 2 warning signs
  • Industry Position: 200% above the Biotechnology median (#1 of 1342)

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
89GF Score

Get the complete analysis for STU:UNC

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€257.90
Price
€210.28
GF Value